How to Define Pathogenicity, Health, and Disease?
- PMID: 27862583
- DOI: 10.1002/humu.23144
How to Define Pathogenicity, Health, and Disease?
Abstract
Scientific and clinical communities produce ever increasing amounts of data and details about health and disease. Our ability to understand and utilize this information is limited because of imprecise language and lack of well-defined concepts. This problem involves also the principal concepts of health, disease, and pathogenicity. Here, a systematic model is presented for pathogenicity, as well as for health and disease. It has three components: extent, modulation, and severity, which jointly define the continuum of pathogenicity. The model is population based, and once implemented, it can be used for numerous purposes such as diagnosis, patient stratification, prognosis, finding phenotype-genotype correlations, or explaining adverse drug reactions. The new model has several benefits including health economy by allowing evidence-based personalized/precision medicine.
Keywords: disease; disease extent; disease modulation; disease severity; health; individual variability; pathogenicity; pathogenicity model; pathogenicity zone.
© 2016 WILEY PERIODICALS, INC.
Similar articles
-
DNA based customized nutraceutical "gene therapy" utilizing a genoscore: a hypothesized paradigm shift of a novel approach to the diagnosis, stratification, prognosis and treatment of inflammatory processes in the human.Med Hypotheses. 2006;66(5):1008-18. doi: 10.1016/j.mehy.2005.09.029. Epub 2006 Jan 5. Med Hypotheses. 2006. PMID: 16403602
-
[Pharmacogenetics: towards personalized medicine].Harefuah. 2005 Oct;144(10):711-6, 750. Harefuah. 2005. PMID: 16281764 Review. Hebrew.
-
[Pharmacogenetics or the promise of a personalized medicine: variability in drug metabolism and transport].Ann Biol Clin (Paris). 2004 Sep-Oct;62(5):499-511. Ann Biol Clin (Paris). 2004. PMID: 15355800 Review. French.
-
Evidence-based pharmacogenetics: Is it possible?Int J Risk Saf Med. 2015;27 Suppl 1:S97-8. doi: 10.3233/JRS-150706. Int J Risk Saf Med. 2015. PMID: 26639733
-
Prediction of in vivo clearance and associated variability of CYP2C19 substrates by genotypes in populations utilizing a pharmacogenetics-based mechanistic model.Drug Metab Dispos. 2015 Jun;43(6):870-83. doi: 10.1124/dmd.114.061523. Epub 2015 Apr 6. Drug Metab Dispos. 2015. PMID: 25845826
Cited by
-
Definitions of parasitism, considering its potentially opposing effects at different levels of hierarchical organization.Parasitology. 2023 Aug;150(9):761-768. doi: 10.1017/S0031182023000598. Epub 2023 Jul 3. Parasitology. 2023. PMID: 37458178 Free PMC article. Review.
-
Individual Genetic Heterogeneity.Genes (Basel). 2022 Sep 10;13(9):1626. doi: 10.3390/genes13091626. Genes (Basel). 2022. PMID: 36140794 Free PMC article. Review.
-
PON-All: Amino Acid Substitution Tolerance Predictor for All Organisms.Front Mol Biosci. 2022 Jun 16;9:867572. doi: 10.3389/fmolb.2022.867572. eCollection 2022. Front Mol Biosci. 2022. PMID: 35782867 Free PMC article.
-
Measuring and interpreting pervasive heterogeneity, poikilosis.FASEB Bioadv. 2021 May 3;3(8):611-625. doi: 10.1096/fba.2021-00015. eCollection 2021 Aug. FASEB Bioadv. 2021. PMID: 34377957 Free PMC article.
-
Mapping OMIM Disease-Related Variations on Protein Domains Reveals an Association Among Variation Type, Pfam Models, and Disease Classes.Front Mol Biosci. 2021 May 7;8:617016. doi: 10.3389/fmolb.2021.617016. eCollection 2021. Front Mol Biosci. 2021. PMID: 34026820 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
